Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Aciclovir

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

129 API Suppliers, 33 USDMF, 19 CEP/COS, 8 JDMF, 11 EU WC, 36 KDMF, 25 NDC API, 54 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

29 Drugs in Development

29 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

466 FDF Dossiers, 98 FDA Orange Book, 178 Europe, 17 Canada, 16 Australia, 30 South Africa, 127 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 6 SPI Pharma, 11 DKSH, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Kirsch Pharma, 4 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 36 BASF, 1 CD Formulation, 3 Corel Pharma Chem, 6 DFE Pharma, 2 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures, 4 Ingredion Pharma Solutions, 12 Kerry, 4 Keval Exports, 1 Kima Chemical, 3 Lonza Capsugel, 14 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 3 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

57 Fillers, Diluents & Binders, 40 Thickeners and Stabilizers, 39 Disintegrants & Superdisintegrants, 30 Direct Compression, 30 Granulation, 26 Topical, 23 Solubilizers, 20 Coating Systems & Additives, 18 Film Formers & Plasticizers, 16 Lubricants & Glidants, 13 Controlled & Modified Release, 13 Chewable & Orodispersible Aids, 13 Parenteral, 13 Taste Masking, 11 Co-Processed Excipients, 8 Emulsifying Agents, 8 Empty Capsules, 6 Rheology Modifiers, 3 Coloring Agents, 3 Surfactant & Foaming Agents, 1 Soft Gelatin, 1 API Stability Enhancers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 49 News #PharmaBuzz

GLOBAL SALES INFORMATION

39 US Medicaid Prescriptions, 78 Regulatory FDF Prices

MARKET PLACE

47 APIs, 23 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 1 US Exclusivities, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 13 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD Tel Aviv - Jaffa IL	CEP 1997-084 - Rev 12	Aciclovir	2024-05-30	Valid	Chemical		968
29/11/2025	ABC Farmaceutici SpA	Italy	ABC Farmaceutici S.p.A. Trecate IT	R0-CEP 2008-169 - Rev 01	Aciclovir, Process B	2011-03-15	Withdrawn by Holder	Chemical	2013-10-11	968

Aciclovir

Aciclovir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

129 API Suppliers

33 USDMF

19 CEP/COS

8 JDMF

11 EU WC

36 KDMF

25 NDC API

54 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

29 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

466 FDF Dossiers

98 FDA Orange Book

178 Europe

17 Canada

16 Australia

30 South Africa

127 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 5%;1%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Rochem International Inc

6 SPI Pharma

11 DKSH

5 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Kirsch Pharma

4 ACG Worldwide

5 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

36 BASF

1 CD Formulation

3 Corel Pharma Chem

6 DFE Pharma

2 Esteem Industries

2 Finar

9 Gangwal Chemicals

1 Ideal Cures

4 Ingredion Pharma Solutions

12 Kerry

4 Keval Exports

1 Kima Chemical

3 Lonza Capsugel

14 Microlex e.U

2 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

4 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

3 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

4 Silverline Chemicals

1 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

CAPSULE;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUSPENSION;ORAL - 200MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 800MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons